REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00663416 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Stroke

Interventions

DRUG: NTx™-265: rhCG, then rEPO
DRUG: Saline placebo

Sponsor

Stem Cell Therapeutics Corp.